Vitiligo showdown: new drug vs. old combo in Head-to-Head trial
NCT ID NCT07368673
First seen Jan 26, 2026
Summary
This study tested whether a newer cream (ruxolitinib) works better alone or when combined with two older creams (tacrolimus and corticosteroids) for vitiligo. 120 adults with limited vitiligo (less than 10% of body affected) were split into three groups and treated for 24 weeks. The goal was to see which approach restores more skin color safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dow University of health sciences
Karachi, Sindh, Pakistan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.